There is now a growing body of evidence [12, 13] that suggests that there may be a role for antiVEGF drugs, both selective and unselective, in the treatment of the wide range of ocular conditions caused by the development of abnormal blood vessels, including exudative DME. [14] Results of large, randomised, controlled trials are needed to confirm early safety and efficacy findings from small, open-label prospective studies. Laser photocoagulation treatment, however, remains the current best treatment for clinically significant exudative DME. The primary aim of this type of laser treatment is to try to stabilise vision rather than to improve it. [15] In ischaemic diabetic maculopathy laser treatment is not an option as it would be expected to make vision worse. There is no known effective treatment for ischaemic DME, the natural history of which is of a gradual decline in central vision. Ischaemia is well known to be a major factor in the development and progression of diabetic retinopathy (DR). It may be due in part to the effects of VEGF on the tone of blood vessel walls and narrowing of small blood vessels. Consequently some studies have been done to try to assess the effect of antiVEGF treatment on retinal ischaemia. The results in the literature are conflicting.